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Recent exciting work partly through The Cancer Genome Atlas has implicated epigenetic 
mechanisms including histone modifications in the development of both pediatric and 
adult high-grade glioma (HGG). Histone lysine methylation has emerged as an important 
player in regulating gene expression and chromatin function. Lysine (K) 27 (K27) is a 
critical residue in all seven histone 3 variants and the subject of posttranslational histone 
modifications, as it can be both methylated and acetylated. In pediatric HGG, two critical 
single-point mutations occur in the H3F3A gene encoding the regulatory histone variant 
H3.3. These mutations occur at lysine (K) 27 (K27M) and glycine (G) 34 (G34R/V), both 
of which are involved with key regulatory posttranscriptional modifications. Therefore, 
these mutations effect gene expression, cell differentiation, and telomere maintenance. 
In recent years, alterations in histone acetylation have provided novel opportunities to 
explore new pharmacological targeting, with histone deacetylase (HDAC) overexpression 
reported in high-grade, late-stage proliferative tumors. HDAC inhibitors have shown 
promising therapeutic potential in many malignancies. This review focuses on the 
epigenetic mechanisms propagating pediatric and adult HGGs, as well as summarizing 
the current advances in clinical trials using HDAC inhibitors.
Keywords: glioblastoma multiforme, diffuse intrinsic brainstem glioma, histone methylation, histone acetylation, 
histone deacetylase inhibitors, epigenetics, high-grade glioma
iNTRODUCTiON
Recent exciting work partly through The Cancer Genome Atlas (TCGA), has implicated epigenetic 
mechanisms including histone modifications in the development of both pediatric and adult high-
grade glioma (HGG). Importantly, epigenetic modifications have a potential for novel therapeutic 
drug targeting as epigenetic changes are catalyzed by highly specific enzyme complexes. For the pur-
pose of this review, the term HGG is used to describe the astrocytic gliomas: anaplastic astrocytoma 
(WHO Grade III) and glioblastoma (WHO Grade IV) (1). The term diffuse intrinsic pontine glioma 
(DIPG) refers to a specific astrocytic glioma, which arises in the ventral pons in children who carries 
a uniformly fatal prognosis, with a median survival of 9 months (1). The annual incidence of adult 
glioblastoma is 7.2 per 100,000, making it the most common adult primary intrinsic brain tumor 
(2). By contrast, in children, HGGs are reported to have an annual incidence of 0.8 per 100,000, 
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representing 8–12% of pediatric central nervous system tumors 
and making them rare compared to other tumor types (2–4).
Unlike genetic abnormalities, epigenetic abnormalities 
encompass modifications that do not result from a change in the 
primary DNA sequence (5). These modifications include DNA 
methylation, histone methylation, and acetylation as well as 
other modifications that can indirectly regulate gene expression 
(5). A classic epigenetic modification in adult glioblastoma is 
DNA hypermethylation of the enzyme O-6-methylguanine-
DNA methyltransferase, which suppresses its normal function 
to remove alkyl groups from DNA (6). This makes such patients 
more sensitive to alkylating agents such as temozolomide (6).
Histones are positively charged proteins namely H1, H2A, 
H2B, H3, and H4, which make up the macromolecular three-
dimensional complex of chromatin together with negatively 
charged DNA (7). The nucleosome is the fundamental subunit 
of chromatin comprising a histone octamer with two copies of 
each of histones H2A, H2B, H3, and H4 (7). Histone H3 has 
seven known sequence variants in mammalian cells, which are 
highly sequence conserved, differing only by a few amino acids. 
These are histones H3.1, H3.2, H3.3, H3.4 (H3T), H3.5, H3.X, 
and H3.Y (8). Histone H3.3 has been shown to function in 
maintaining genome integrity during mammalian development, 
by supporting chromosomal chromatin structures (9). This 
histone variant is known to modulate specific chromatin changes 
and gene expression profiles and is often considered a mark of 
transcriptional activity (10).
Chromatin remodeling or modification represents a highly 
dynamic process in which there is continual laying down and 
removal of modifications by chromatin-remodeling enzymes 
resulting in three-dimensional changes, which can affect 
gene expression by regulating access to RNA polymerases and 
transcription factors (11). In particular, the N-terminal tails of 
histones contain lysine (K) and arginine (R) residues that can 
undergo posttranslational modifications including acetylation, 
methylation, ubiquitylation, and sumoylation, as well as serines 
that can be phosphorylated (11). These complex modifications 
affect almost all DNA-dependent processes, including gene 
expression, DNA replication and repair, and centromere and 
telomere maintenance (11, 12). Therefore, cross-talk between 
modifications may lead to myriad read-outs, which are beyond 
the scope of this review. We will therefore focus mainly on the 
posttranslational modification of histones by methylation and 
acetylation, as these are of current clinical interest in adults and 
pediatric HGG, and both processes are novel pharmacological 
targets with recent early phase clinical trials.
HiSTONe MeTHYLATiON iN PeDiATRiC 
GLiOMA
H3F3A K27M and G34R/v Histone 
Mutations in Pediatric HGG
Schwartzentruber et al. were the first to report recurrent mutations 
of a regulatory histone, H3F3A, in humans by exome sequenc-
ing of pediatric glioblastomas (see Figure  1) (13). The histone 
H3F3A encodes the histone variant H3.3, which is predominantly 
incorporated into transcription sites and telomeric regions, and 
is associated with active and open chromatin (14). Mutations in 
H3F3A involve two critical single-point mutations in the histone 
tail at lysine (K) 27 (K27M) and glycine (G) 34 (G34R/V), both 
of which are involved with key regulatory posttranscriptional 
modifications (13). As well as being reported in pediatric HGGs, 
H3.3 mutation are also reported in other childhood cancers such 
as chondroblastomas and giant cell tumors of the bone (15).
Histone lysine methylation has emerged as an important 
player in regulating gene expression and chromatin function. 
K27 is a critical residue in all seven histone 3 variants, and it can 
be posttranslationally methylated or acetylated (16). Acetylation 
may induce active transcription, while monomethylation, 
dimethylation or trimethylation of K27, catalyzed by the histone 
methyltransferase enhancer of zeste homologue 2 (EZH2), are 
repressive marks associated with gene silencing (5). The K27M 
mutation in certain cases results in decreased dimethylation and 
trimethylation of H3K27 and is associated with transcriptional 
activation; however, there are alternative mechanisms by which 
the K27M increases trimethylation, thus silencing tumor sup-
pressor gene expression (17). This occurs through bivalent 
domains, which occur on histone proteins and allow epigenetic 
regulators such as methylating enzymes to silence or activate 
gene expression (17). Similarly, the G34R/V mutation results in 
redistribution of H3K36 methylation and altered gene transcrip-
tion, including upregulation of the MYCN (V-Myc avian myelo-
cytomatosis viral oncogene neuroblastoma-Derived Homolog) 
oncogene (13, 18, 19).
Importantly, H3F3A mutations have been reported to have 
100% specificity for pediatric HGGs, with no evidence of the 
mutations in pediatric low-grade gliomas, embryonal tumors, or 
ependymomas (20). Furthermore, several groups have reported 
that these histone H3.3 mutations are not identified in adult 
glioblastoma (20–22). Moreover, K27M and G34R/V mutations 
are associated with differing age and tumor location in childhood 
HGGs (13, 16, 23). K27M histone H3.3 mutations occur more 
commonly in younger children (median age 10.5  years, range 
5–23 years) and are present in 70–80% of midline brainstem and 
thalamic glioblastoma (13, 16, 23). G34R/V histone H3.3 muta-
tions have been shown to occur more frequently in older children 
(median age 18 years, range 9–42 years) and are observed almost 
exclusively in hemispheric gliomas (16, 23).
The K27M histone H3.3 mutation is associated with a shorter 
clinical survival [0.73 years (±0.48)] (p = 0.0008) compared with 
patients lacking the mutation [4.59 years (±5.55)]. However, this 
poor survival may in part reflect the brainstem and midline loca-
tions of these pediatric gliomas (16).
K27M Mutated Pediatric HGG, Polycomb 
Repressive Complex 2 (PRC2), and the 
Global Hypomethylator Phenotype
The PRC2 is one of the two complexes of polycomb group proteins; 
the other component of this group of proteins is the polycomb 
repressive complex 1 (PRC1). Both PRC2 and PRC1 are often 
needed to maintain gene repression (24). PRC2 is required for the 
initial targeting of the genomic region [PRC response elements] 
FiGURe 1 | Alterations in histone methylation in pediatric and adult high-grade glioma. In children, two single-point mutations in the regulatory histone, 
H3F3A, occur in the histone tail at H3.3 K27M and G34R/V, affecting key regulatory posttranscriptional modifications. H3.3 K27M mutated glioblastoma displays 
reprogramming of H3K27 methylation. K27M alters the enzymatic activity of EZH2, the catalytic subunit of PRC2, which establishes H3K27 methylation. This leads 
to a global reduction in H3K27 methylation and the CHOP, priming for increased gene expression, cell differentiation, and alternative lengthening of telomeres. Within 
a globally hypomethylated phenotype, K27M mutated glioma may allow increased H3K27 methylation at specific gene loci. An increased H3K27 methylation 
silences tumor suppressor gene expression, such as p16INKA. In H3.3 G34R/V mutated glioma, mutations in SETD2 lead to decreased H3K36 methylation, which 
results in increased gene expression and alternative lengthening of telomeres. MYCN is upregulated through differential genomic binding of methylated H3K36 in 
G34R/V mutated glioblastoma. In adults, mutated IDH1 and induction of the G-CIMP phenotype lead to the overproduction of 2-HG. 2-HG inhibits histone 
demethylases leading to increased H3K27 methylation, which leads to a block in cell differentiation, and aberrant DNA and histone methylation. Over production of 
2-HG also inhibits ten-eleven translocation (TET) activation, leading to a decrease in the 5hmC/CHTOP/methylosome complex, which is normally present in 
wild-type IDH1 glioma. This results in decreased transactivation of cancer-related genes such as EGFR, AKT, CDK, and BRAF and may provide an explanation for 
increased survival in patients with IDH1 mutated glioblastoma. AKT, protein kinase B; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDK, cyclin-dependant 
kinase; CHOP, CpG hypomethylator phenotype; CHTOP, chromatin target of PRMT1; EGFR, epidermal growth factor receptor; EZH2, enhancer of zeste homologue 
2; G-CIMP, glioma-CpG-island methylator phenotype; G34R/V, glycine34 arginine/valine; H3F3A, H3 histone family 3A; H3K27me2/3, histone 3 lysine 27 
dimethylation/trimethylation; H4R3, histone 4 arginine 3; 2-HG, 2-hydroxyglutarate; 5hmC, 5-hyroxymethylcytosine; K27M, lysine 34 methionine; PRC2, polycomb 
repressive complex 2; SETD2, SET domain-containing 2; TET family, ten-eleven translocation family; +, increased; −, decreased; dotted line, alternative pathway in 
G34R/V mutated glioma.
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to be silenced, while PRC1 is thought to work downstream of 
PRC2 and stabilizes the cellular memory of the silenced region 
after cellular differentiation (24).
The PRC2 complex has histone methyltransferase activity 
and silences gene expression by dimethylating or trimethylating 
H3K27 through its enzymatic subunits, enhancer of zeste homolog 
1 and 2 (EZH1 and EZH2) (24, 25). Lewis et  al. reported that 
PRC2 is inhibited by aberrant binding of mutant K27M to EZH2 
(26). Moreover, K27M alters the enzymatic activity of EZH2, the 
catalytic subunit of PRC2, which establishes H3K27 methylation, 
thereby leading to a global reduction of H3K27 methylation and 
the loss of gene repression (see Figure 1) (26, 27).
Bender et  al. used chromatin immunoprecipitation, next-
generation sequencing, and whole-genome bisulfite sequencing 
on primary HGGs, to show reduced methylation of H3K27 
primes generally for global DNA hypomethylation (28). This 
leads to the CpG hypomethylator phenotype (CHOP), resulting 
in the activation of gene expression and cell differentiation (see 
Figure 1) (28).
Subsequently, although mutant K27M results in a global 
reduction of H3K27 methylation in HGGs, Chan et  al. have 
reported that at specific gene loci there is a dramatic increase in 
H3K27 methylation, as well as an increase in the catalytic subunit 
of the PRC2 histone methyltransferase EZH2 (17, 29). Although 
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DNA hypomethylation promotes gene expression, it would be 
disadvantageous to tumor cells if this included the expression of 
genes protecting against tumorigenesis, such as tumor suppressor 
genes. Therefore, Chan et al. have proposed that by inducing a 
globally hypomethylated phenotype (CHOP), this allows for 
increased binding of PRC2 and establishment of H3K27 methyla-
tion at specific gene loci (29). It is likely that tumor formation in 
H3.3 K27M mutated HGGs is driven by chromatin modifications 
occurring due to the loss and gain of H3K27 methylation at dif-
ferent gene loci (see Figure 1) (29). This correlates, for example, 
with a gain of H3K27 methylation at p16INKA4A and decreased 
expression of this tumor suppressor gene, consistent with promo-
tion of tumorigenesis (see Figure 1) (29).
Upregulation of MYCN in G34R/v Mutated 
Pediatric HGG
By a similar mechanism to H3K27, histone H3K36 is also subject 
to alterations in methylation (30). Although still occurring in 
pediatric gliomas with mutations in the histone tail of H3.3, 
the mutation is G34R/V as opposed to K27M. Fontebasso et al. 
conducted whole exome sequencing on 60 pediatric HGGs and 
compared them to 543 non-cancer control samples (30). They 
showed that decreased methylation of H3K36 has been shown 
to occur through loss of function mutations in the H3K36 
methyltransferase SET domain-containing 2 (30). The decrease 
in H3K36 trimethylation was shown to correlate with increased 
gene expression (30).
In addition, the G34R/V mutation was shown to upregulate 
MYCN, with increased RNA polymerase II binding and tran-
scriptional upregulation at the gene locus, through the differential 
genomic binding of methylated H3K36 to specific gene loci (see 
Figure  1) (19, 31). MYCN is a potent oncogene implicated in 
many cancers, often signaling an aggressive and undifferentiated 
phenotype. Of recent discovery, forced overexpression of MYCN 
has been shown to cause glioblastoma in the developing mouse 
forebrain, providing evidence for a tumor-initiating event that 
may drive pediatric glioblastoma formation during neurological 
development (19, 32).
These insights provide opportunities for novel ways to target 
specific genetic and epigenetic aberrations in H3.3 G34R/V 
mutated pediatric HGGs.
Putative Telomere Maintenance in G34R/v 
Mutated Pediatric HGG
G34R/V mutations occurring in hemispheric pediatric HGG, fre-
quently display mutations in TP53, ATRX (α-thalassemia/mental 
retardation syndrome X-linked), and DAXX (death domain-
associated protein), unlike the K27M mutated HGGs (13, 16, 
23, 33). Schwartzentruber et al. reported 100% of patients with 
H3.3 mutated G34R/V glioblastoma and who had mutations in 
ATRX and DAXX, which encode two subunits required for H3.3 
incorporation at centromeres and telomeres (13, 34, 35).
Pathak et al. further investigated mutations in the H3.3-ATRX-
DAXX chromatin remodeling pathway in pediatric glioblastoma 
(36). They reported a global loss of histone methylation in 80% of 
cases, particularly a loss of trimethylation in histones H3K27 and 
H3K4 (36). The combinatorial methylation loss of these histones 
was associated with H3F3A-ATRX mutations, with 60% of K27M 
cases and 75% of G34R mutant cases displaying ATRX loss (36).
H3F3A/ATRX-DAXX/TP53 mutations are strongly associ-
ated with alternative lengthening of telomeres, a telomerase-
independent telomere maintenance mechanism that could allow 
unlimited cellular proliferation in pediatric glioblastoma (13, 33, 
37, 38).
HiSTONe MeTHYLATiON iN ADULT 
GLiOMA
The Hypermethylator Phenotype Glioma-
CpG-island Methylator Phenotype 
(G-CiMP) is Distinct from H3F3A 
Mutations, Occurring Rarely in Pediatric 
Glioma but More Frequently in Young 
Adults
A high proportion of low-grade gliomas and secondary glio-
blastomas have been shown to harbor mutations in isocitrate 
dehydrogenase 1 and 2 (IDH1/IDH2) (see Figure 1) (39). IDH1 
is an enzyme involved in the Krebs cycle of glucose metabolism 
(40). Its usual function is to decarboxylate isocitrate to yield 
α-ketoglutarate (40). The mutation of IDH1 results in loss of nor-
mal enzymatic function and leads to the abnormal production of 
2-hydroxyglutarate (2-HG) (40). 2-HG has been found to inhibit 
histone and DNA demethylases, causing widespread changes in 
histone and DNA methylation and potentially promoting tumo-
rigenesis (40).
Although IDH1 mutations are relatively uncommon in pedi-
atric glioblastoma, single amino acid substitutions of arginine 
result in gain of function mutations in IDH1 [commonly arginine 
to histidine (R132H)] and occur frequently in young adults with 
secondary glioblastoma, which has progressed from lower grade 
neoplasms (41, 42). IDH1 mutational status has been shown to be a 
positive prognosticator for survival in patients with glioblastoma. 
IDH1 indirectly affects H3K27 or H3K36 methylation by the 
oncometabolite 2-HG (43). 2-HG inhibits histone demethylases 
and is associated with a distinct G-CIMP, specifically increasing 
methylation of H3K27 and H3K36, which has been associated 
with a block in cell differentiation (see Figure  1) (43–45). 
Furthermore, the IDH1 mutations promoting methylation are 
associated with mutations in TP53 (13). This represents a third 
subgroup of pediatric and young adult glioblastoma, which is 
mutually exclusive from H3F3A mutations (23). The importance 
of identifying IDH1 mutation status is important for prognosis in 
this subgroup, with the opportunity to explore 2-HG inhibition 
and the potential to prevent the transformation of a low-grade 
malignancy to a HGG (43).
Mutation-independent Downregulation of 
H3.3 Favors Self-Renewal in Adult 
Glioblastoma Cancer Cells
Recent breakthrough by Dirk et  al. has provided a pos-
sible explanation for the paucity of H3.3 mutations in adult 
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glioblastoma, by mutation-independent abnormalities in 
histone biology (46). By using patient-derived glioblastoma 
primary cultures that enrich for cells with tumor-initiating 
and self-renewal potential, they demonstrated that DNA meth-
ylation profiles in H3F3A wild-type adult glioblastoma were 
similar to DNA methylation profiles of H3.3 mutated pediatric 
glioblastoma (46).
Mixed lineage leukemia 5 (MLL5) is the most divergent 
member of the MLL family. Its biological role is not fully 
characterized; however, it is known to lack methyltransferase 
function (47). To identify if epigenetic modifiers are implicated 
in the downregulation of H3.3 in adult glioblastoma, Dirk 
et  al. investigated gene expression profiling across glioblas-
toma self-renewing cultures and found MLL5 to be expressed 
robustly (46). Overexpression of MLL5 in glioblastoma primary 
cultures led to decreased H3.3, while knockdown of MLL5 led 
to increased H3.3 protein, showing a direct role for MLL5 in 
repressing H3.3 (46). Furthermore, MLL5 overexpression led 
to increased expression of two chromatin condensing genes; 
therefore, MLL5 may exert transcriptional repression of H3.3 
(via H3F3B) by altering chromatin configuration and acces-
sibility (46).
Finally, histone demethylase inhibitors were tested in glio-
blastoma primary cultures and were shown to have potent sup-
pressive effects of glioblastoma self-renewal (46). These findings 
suggest that chromatin remodeling could be exploited as a novel 
therapeutic target in adult glioblastoma.
Overproduction of 2-HG inhibits the  
Ten-eleven Translocation (TeT) Family  
and H3K27 Demethylases in Adult HGG
Histone modifications occur less commonly in adults compared 
to children; however, mechanisms of glioma propagation have 
been explored with regards to H3K27 and histone 4 arginine 
3 (H4R3) methylation. Epigenetic modifications of histone 
proteins occur through IDH1 mutation and induction of the 
G-CIMP phenotype (48). Subsequent overproduction of 2-HG 
inhibits the TET family of 5-hyroxymethylcytosine (5hmC) 
hydroxylases leading to a decrease in 5hmC (49). 2-HG also 
inhibits H3K27 demethylases leading to an increase in H3K27 
methylation, with resulting aberrant histone and DNA meth-
ylation, as well as a block in cell differentiation (see Figure 1) 
(43, 45).
Taiki et  al. showed that glioblastoma cells with wild-type 
IDH1 contain increased TET and 5hmC levels, and TET-1 pro-
duction of 5hmC is required for gliomagenesis, by recruiting 
the chromatin target of PRMT1–methylosome complex (50). 
5hmC has been previously reported to act as an intermediate 
for DNA demethylation but instead recruits DNA-binding 
proteins (50, 51). The methylosome is an arginine methyltrans-
ferase complex that promotes PRMT1-mediated methylation 
of H4R3 in genes involved in gliomagenesis, including EGFR, 
AKT3, CDK6, CCND2, and BRAF (see Figure  1) (50). This 
provides a mechanism by which patients with mutated IDH1 
have a better survival compared to those with wild-type IDH1 
(52, 53).
Histone Acetylation in Pediatric and Adult 
HGG—A Balancing Act between Histone 
Acetyltransferases (HATs) and Histone 
Deacetylases (HDACs)
As well as undergoing methylation, histone tails can be also post-
translationally modified by acetylation (54). The balance of action 
between HATs and HDACs is a key regulatory mechanism in 
the transcriptional activation and repression of gene expression, 
respectively (54). HDACs are overexpressed in many cancers, 
and targeting with HDAC inhibitors has provided a promising 
avenue in the development of new therapeutic approaches (55). 
HDACs facilitate the condensation of chromatin, by removing 
acetyl groups from the N-terminal tails of histone proteins, 
preventing the access of transcriptional machinery to DNA, and 
by binding of SWI3, ADA2, N-CoR and TFIIIB (SANT) contain-
ing proteins (56). SANT containing proteins bind unacetylated 
proteins, inhibiting HATs and facilitating HDAC binding (54, 
56). There are 18 HDAC enzymes, and these are classified as zinc 
dependent (class I, IIa, IIb, and IV) or zinc independent and 
NAD dependent (class III) (55). It is particularly class I and II 
HDACs, which have become the focus for targeting as anticancer 
therapies (55). Class I HDACs associate with multiprotein com-
plex repressors and have a role in cell survival and proliferation 
(55, 57–60). Class IIa HDACs have tissue-specific roles, and class 
IIb HDACs have been identified in the regulation of cell survival 
in response to stress (58, 61). There are non-histone protein 
targets of HDACs, including hormone receptors, transcription 
factors, and DNA repair enzymes (60, 62). The recent advances 
in the targeting of HDACs with HDAC inhibitors is therefore a 
complex process due to the lack of HDAC inhibitor specificity 
for histone proteins and little understanding of their mechanism 
of action (60, 62, 63).
Altered expression of HDACs in Adult and 
Pediatric Glioblastoma
The Cancer Genome Atlas used genome-wide sequencing of 
284 glioblastoma samples to identify somatic mutations in genes 
involved with histone modifications and identified somatic muta-
tions in HDAC2 (64).
Lucio-Etevoric et al. evaluated mRNA expression of class I, II, 
and IV HDACs in 20 low-grade gliomas (13 grade I and 7 grade 
II) and 23 HGGs (5 grade III and 18 glioblastomas), with patient 
ages ranging from 1.3 to 79 years (mean age 24.6  years, SD of 
12.8 ± 22.6 years) (65). They reported hypoexpression of HDACs 
II and IV in glioblastoma compared to low-grade gliomas and 
normal brain tissue (65). In contrast, HDAC I overexpression 
has been reported in high-grade, late-stage proliferative tumors, 
supporting the rationale for the use of HDAC inhibitors in 
promoting the re-expression of silenced tumor suppressor genes 
in glioblastoma, as well as a more open chromatin structure 
facilitating access for DNA damaging agents (66, 67). Therefore, 
HDACs may have a role in repressing genes associated with 
gliomagenesis, and HDAC inhibitors may not be effective in all 
cases of glioblastoma, as they may potentiate the transcriptional 
activation of proto-oncogenes (65, 68).
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PHARMACOLOGiCAL TARGeTiNG OF 
HiSTONe MODiFieRS iN HGG
Pediatric HGG Trials Using HDAC 
inhibitors
Tables 1 and 2 summarize completed phase I and phase II trials 
investigating the use of HDAC inhibitors, in pediatric and adult 
gliomas. The Children’s Oncology Group has conducted two tri-
als investigating the use of the pan-HDAC inhibitor vorinostat 
as a therapy for pediatric HGG (69, 70). They investigated 
vorinostat administered singly or in combination 13-cis retinoic 
acid (isotretinoin) in children with refractory solid tumors (69). 
They showed the maximum tolerated dose (MTD) of vorinostat 
was 230  mg/m2/dose as a single agent or 180  mg/m2/dose 4× 
per week with and 13cRA 80  mg/m2/dose 2× daily, days 1–14 
every 28  days (69). Dose-limiting toxicities for vorinostat as a 
single agent included neutropenia, thrombocytopenia, and 
hypokalemia (69). Dose-limiting toxicities for vorinostat and 
13cRA included neutropenia, thrombocytopenia, anorexia, and 
hypertriglyceridemia (69). Prolonged stable disease was observed 
in five patients including one of seven with DIPG, and a complete 
response was observed in one patient with neuroblastoma (69).
A second phase I study by the Children’s Oncology Group 
investigated vorinostat with the alkylating agent temozolomide 
in relapsed or refractory primary CNS tumors and showed that 
300 mg/m2/day of vorinostat in combination with 150 mg/m2/day 
of temozolomide is well tolerated in 5-day cycles every 28 days 
(70). Myelosuppression was the major dose-limiting toxicity 
(70). Stable disease was observed in one of seven patients with 
HGG (70). An ongoing phase I/II trial for newly diagnosed 
glioblastoma is investigating vorinostat with radiotherapy and 
concomitant temozolomide (71).
A further phase I trial conducted by the Children’s Oncology 
Group investigated vorinostat in combination with bortezomib, 
a selective inhibitor of the ubiquitin–proteasome pathway, in 
children with recurrent or refractory solid tumors (72). This 
showed a MTD of vorinostat 230  mg/m2/day on days 1–5 and 
8–12 of a 21-day cycle and bortezomib 1.3 mg/m2 on days 1, 4, 8, 
and 11 of the same cycle (72). Dose-limiting toxicities included 
sensory neuropathy, nausea, and anorexia (72). Six of twenty-
three patients had a malignant glioma; no objective response was 
observed in any of the patients (72).
The Children’s Oncology Group has also conducted a phase I 
trial investigating the HDAC inhibitor valproic acid in children 
with refractory solid or CNS tumors (73). They showed that 
valproic acid administered three times daily to maintain trough 
concentrations of 75–100 μg/mL was well tolerated by patients. 
No dose-limiting toxicities were observed at this dose. Of four 
patients with DIPG, one patient (glioblastoma) was observed to 
have a confirmed partial response and one patient (DIPG) was 
observed to have a minor response (73).
Ongoing clinical trials are investigating event-free survival in 
children with newly diagnosed HGGs and brainstem gliomas, 
using valproic acid with radiotherapy, followed by bevacizumab 
(74). A phase II/III trial is ongoing having recruited children with 
HGG and is studying the event-free survival using vorinostat, or 
temozolomide, or bevacizumab in combination with radiotherapy, 
followed by treatment with bevacizumab and temozolomide (75).
Adult HGG Trials Using HDAC inhibitors
The North Central Cancer Treatment Group has conducted two 
phase II trials looking at vorinostat as a treatment for glioblastoma 
(76, 77). The first trial using vorinostat as a single agent found 
that it had modest activity in patients with recurrent glioblastoma 
(76). A cohort of 66 patients was treated, and median overall sur-
vival from study entry was 5.7 months (range 0.7–28+ months) 
with a median time to progression of 1.9  months (range 
0.3–28+  months). Interestingly, 15% of patients were progres-
sion free at 6 months, and their duration of disease stability was 
long with a median of 11.2 months (range 6.8–28+ months) (76). 
This study revealed a subpopulation who benefit from HDAC 
inhibitor therapy, with the potential to investigate vorinostat in 
combination with other therapies, as well as its effect on newly 
diagnosed glioblastoma (76).
The second trial by the North Central Cancer Treatment 
Group investigated vorinostat in combination with the protea-
some inhibitor bortezomib, in patients with recurrent glio-
blastoma (77). Unfortunately, in this trial, the progression-free 
survival at 6  months was 0%, median time to progression was 
1.5 months (range 0.5–5.6 months), and median overall survival 
was 3.2 months (77). Therefore, this combination was not rec-
ommended for further investigation in patients with recurrent 
glioblastoma (77).
A phase I/II trial using the HDAC inhibitor romidepsin was 
conducted by the North American Brain Tumor Consortium for 
adults with recurrent malignant glioma (78). Thirty-five patients 
with recurrent glioblastoma were entered to the study, and the 
median overall survival was 34  weeks (95% CI, 21–47  weeks) 
(78). This showed that there was no significant clinical activity of 
romidepsin as a single agent in unselected patients with recurrent 
glioblastoma, and so it was concluded to be ineffective (78).
Panobinostat is an HDAC inhibitor with anti-angiogenic 
activity and has been tested in a phase I trial with the anti-VEGF 
monoclonal antibody bevacizumab, in patients with recurrent 
HGG (79). The recommended doses were oral panobinostat 
30 mg three times per week, every other week, with bevacizumab 
10 mg/kg every other week (79). The major dose-limiting toxicity 
was thrombocytopenia (79). The trial was escalated to phase II 
for patients with recurrent glioblastoma and recurrent anaplastic 
glioma; however, of 24 patients with glioblastoma, median overall 
survival was 9 months (range 6–19 months), and the glioblastoma 
cohort of the trial was closed at interim analysis (80). The trial was 
completed in anaplastic glioma patients, with a median overall 
survival of 17 months (range 5–27 months) (80). Panobinostat 
in combination with bevacizumab was concluded to be no more 
effective than bevacizumab alone; this is hypothesized to be due 
to diminished transport of panobinostat and bevacizumab across 
the blood–brain barrier (80). Preclinical evidence has shown that 
panobinostat may act as a radiosensitizer, and recently, a phase 1 
trial combining panobinostat with stereotactic re-irradiation in 
patients with recurrent HGG has been reported (81). The results 
were more promising than panobinostat with bevacizumab, with 
TABLe 1 | Summary of completed phase i clinical trials investigating histone deacetylase inhibitors for the treatment of adult and pediatric high grade glioma.
Clinical trial Phase Population Results Clinical observations Reference
Maximum tolerated dose Dose-limiting toxicities
Vorinostat or vorinostat 
and 13-cis retinoic acid
I Pediatric: Refractory 
solid tumors or 
leukemias
Vorinostat 230 mg/m2/dose and vorinostat 180 mg/m2/dose 4× per week 
and 13cRA 80 mg/m2/dose 2× daily, days 1–14 every 28 days
Single agent: neutropenia, 
thrombocytopenia, and 
hypokalemia
Prolonged stable disease in 1/7 
with diffuse intrinsic pontine 
glioma (DIPG)
(62)
Combination therapy: 
thrombocytopenia, 
neutropenia, anorexia, and 
hypertriglyceridemia
Vorinostat and 
temozolomide
I Pediatric: Relapsed or 
refractory primary brain 
or spinal cord tumors
Vorinostat 300 mg/m2/day and temozolomide 150 μg/m2/day, 5-day 
cycles every 28 days
Myelosuppression Stable disease in 1/7 with high-
grade glioma (HGG)
(63)
Valproic acid I Pediatric: Refractory 
solid or CNS tumors
Valproic acid 3× daily to maintain rough concentrations of 75–100 μg/mL None Response in 2/4 with DIPG (1 
partial and 1 minor)
(66)
Vorinostat and 
bortezomib
I Pediatric: Refractory or 
recurrent solid tumors 
(6/23 malignant glioma)
Vorinostat 230 mg/m2/day, days 1–5 and 8–12 of 21-day cycle, 
bortezomib 1.3 mg/m2/day on days 1, 4, 8, and 11 of a 21-day cycle
Sensory neuropathy, nausea, 
anorexia
No objective responses observed (65)
Panobinostat and 
bevacizumab
I Adult: Recurrent HGG Panobinostat 30 mg 3× per week, every other week, with bevacizumab 
10 mg/kg every other week
None 3/12 partial response, 7/12 stable 
disease
(72)
Vorinostat, bevacizumab 
and irinotecan
I Adult: Recurrent 
glioblastoma
Vorinostat 400 mg twice daily on days 1–3 and 15–17, every 28 days Fatigue, hypertension/
hypotension, and central 
nervous system ischemia
Overall survival 7.3 months (83)
Vorinostat and 
isotretinoin, or vorinostat 
and isotretinoin and 
carboplatin
I Adult: Recurrent 
malignant glioma
Vorinostat 400 mg/day, days 1–14, isotretinoin 100 mg/m2/day, days 
1–21
Elevated AST, 
hypertriglycidemia
Progression-free survival at 
6 months in 10/55 patients (7/10 
had glioblastoma)
(84)
Carboplatin excessive toxicity, replaced with temozolomide. Vorinostat 
500 mg/day, days 1–7 and 15–21, isotretinoin 100 mg/m2/day, days 
1–21, temozolomide 150 mg/m2/day, days 1–7 and 15–21
None
Panobinostat with 
fractionated stereotactic 
re-irradiation therapy
I Adult: HGG Panobinostat 30 mg 3× weekly during radiotherapy. Radiation dose was 
35 in 3.5 Gy fractions given over 2 weeks
Thrombocytopenia, 
neutropenia, prolonged QTc
Progression-free survival at 
6 months in 30 mg cohort, 5/6 
patients. Median overall survival 
in 30 mg cohort 16.1 months
(74)
Vorinostat and 
temozolomide
I Adult: HGG Vorinostat 500 mg days 1–7 and 15–21 of every 28-day cycle in 
combination with temozolomide150 mg/m2/day days 1–5 of every 28-day 
cycle
Anorexia, alternative 
lengthening of telomeres 
rise, thrombocytopenia, 
hemorrhage
Not specified (85)
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TABLe 2 | Summary of phase ii clinical trials investigating histone deacetylase inhibitors in pediatric and adult high-grade glioma (HGG).
Clinical trials Phase Population Drug regimen Side effects Results Reference
Panobinostat II Adult: Recurrent HGG Panobinostat 30 mg 3× per week, every other week, with 
bevacizumab 10 mg/kg every other week
Bone marrow toxicity and 
hypophosphatemia
Glioblastoma arm closed at interim analysis, median 
overall survival 9 months (range 6–19 months). 
Anaplastic glioma arm to completion, median overall 
survival 17 months (range 5–27 months)
(73)
Vorinostat II Adult: Recurrent 
glioblastoma, receiving 
≤1 chemotherapy 
regimes for progressive 
disease
200 mg 2× daily for 14 days, then 7-day rest Thrombocytopenia, fatigue, 
hyponatremia, dehydration
Median overall survival 5.7 months (range 
0.7–28+ months), 9/52 patients progression free 
at 6 months with median duration of stable disease 
11.2 months (range 6.8–28+ months)
(69)
Vorinostat and 
bortezomib
II Adult: Recurrent 
glioblastoma
400 mg daily for 14 days of a 21-day cycle, 1.3 mg/
m2 bortezomib days 1, 4, 8, and 11
Bone marrow toxicity, 
fatigue, neuropathy
0/34 progression free at 6 months (70)
Romidepsin I/11 Adult: Recurrent HGG 13.3 mg/m2/day on days 1, 8, and 15 of each 28-day cycle Bone marrow toxicity and 
fatigue
Median overall survival 34 weeks (95% confidence 
interval 21–47 weeks)
(71)
Radiotherapy with 
temozolomide and 
valproic acid
II Adult: Newly diagnosed 
glioblastoma
Valproic acid, 25 mg/kg, 2× daily. First valproic acid dose 
1 week before the first day of radiotherapy at 10–15 mg/kg/
day
Bone marrow toxicity, 
neurological toxicity, 
metabolic toxicity
Median overall survival 29.6 months (range 
21–63.8 months)
(75)
Vorinostat, 
temozolomide, 
and radiotherapy
I/II Adult: Newly diagnosed 
glioblastoma
Vorinostat 300 mg/day, days 1–5 weekly during radiotherapy 
and with temozolomide, after 4–6 weeks break, up to 12 
cycles of vorinostat 400 mg/day, days 1–7 and 15–21 with 
temozolomide
Neutropenia, 
thrombocytopenia and 
lymphopenia
Time to progression 8.05 months (95% confidence 
interval 6.21–9.30)
(64)
Vorinostat, 
bevacizumab, and 
temozolomide
I/II Adult: Recurrent 
malignant glioma
Vorinostat 400 mg/day, days 1–7 and 15–21 of each 
28-day cycle, temozolomide daily dosing at 50 mg/m2/day, 
bevacizumab 10 mg/kg every other week starting day 1
Bone marrow toxicity, 
seizure, venous 
thromboembolism
Median overall survival 12.5 months (95% confidence 
interval 8.8–14.3 months)
(82)
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a progression-free survival at 6 months of 83% in the panobinostat 
and stereotactic re-irradiation therapy group, compared to 30.4% 
in the panobinostat with bevacizumab group (80, 81). It would be 
interesting to investigate this further via a phase II trial and assess 
the efficacy of the synergistic relationship between panobinostat 
and fractionated stereotactic re-irradiation therapy.
Valproic acid is an antiepileptic drug with HDAC inhibitor 
activity. A phase II trial investigated concurrent radiotherapy, 
temozolomide, and valproic acid in 37 patients with newly diag-
nosed glioblastoma (82). Median overall survival was 29.6 months 
(range 21–63.8 months) (82). Compared to five other phase II tri-
als investigating radiotherapy and temozolomide with radiation 
modifiers including erlotinib, enzastaurin, and poly-ICLC, this 
result shows a large increase in overall survival, with the other 
studies showing overall survivals from 8.6 to 9.3 months (83–87). 
This observation is further supported by a retrospective study 
conducted by Weller et al. Patients with glioblastoma receiving 
radiotherapy alone or radiotherapy with temozolomide were 
analyzed to investigate the effect of antiepileptic therapy given 
during this treatment time (88). They found the overall survival 
was similar for patients taking an antiepileptic drug versus those 
who were not, except for those taking the HDAC inhibitor val-
proic acid (88). Patients taking valproic acid had a better overall 
survival benefit from radiotherapy with temozolomide (hazard 
ratio 0.39, 95% confidence interval 0.24–0.63), compared to those 
taking another antiepileptic drug or no antiepileptic drug (88).
A phase I/II trial investigated the efficacy of vorinostat in 
combination with bevacizumab and daily temozolomide in 
recurrent glioblastoma (89). Dose-limiting toxicities included 
bone marrow toxicity, hyperglycemia, pulmonary embolism, 
bowel perforation, and intracranial hematoma (89). The 6-month 
progression-free survival was 52.4% (95% CI, 36.4–66.1%) (89). 
The best radiographic responses were 2 complete responses, 17 
partial responses, and 20 stable responses, with 1 radiographic 
progression (89). This trial provides promising insight into the 
efficacy of bevacizumab, temozolomide, and vorinostat on recur-
rent glioblastoma with reasonable toxicity (89).
Histone deacetylase inhibitors as a monotherapy for HGGs 
seem disappointing; however, the latest trials investigating HDAC 
inhibitors as part of a combination therapy seem promising in 
improving prognosis in this difficult to treat malignancy, with 
further ongoing studies that are yet to be published (81, 90–92).
FUTURe DiReCTiONS
Histone Demethylase inhibition in 
experimental Models
With increasing knowledge of oncogenic epigenetic changes 
underlying HGGs, such as the H3.3 K27M mutation, targeting 
to reverse these changes has been explored, although to date the 
field is far less advanced than HDAC inhibition. Hashizume et al. 
explored inhibiting JMJD3, the H3K27 demethylase, with GSKJ4 
as a therapeutic strategy for pediatric HGG (93). By increasing 
H3K27 methylation, this could inhibit gene expression that 
would drive gliomagenesis, as well as blocking cell differentiation 
(94). H3.3 K27M glioma cell lines showed 50% growth reduction, 
more apoptosis, and complete inhibition of clonal growth with 
GSKJ4 treatment, while JMJD3 depleted glioma cell lines showed 
no significant reduction in proliferation (93, 94). In athymic (nu/
nu genotype, BALB/c background) mice with brainstem K27M 
glioma xenografts, GSKJ4 treatment resulted in significant tumor 
growth reduction and extended survival (93, 94).
Combination Therapy is Synergistic
With the knowledge of H3.3 mutations and subsequent aber-
rant histone methylation, a recent study by Grasso et  al. has 
investigated the use of the pan-HDAC inhibitor panobinostat, 
with the histone demethylase inhibitor GSKJ4 (95). They used 
a panel of 14 patient-derived DIPG cell cultures, obtained from 
both biopsy and autopsy samples (95). Western blot analyses of 
cells expressing the H3.3 K27M mutation showed that following 
panobinostat treatment, there was an increase in H3 acetylation 
and H3K27 methylation, suggesting there is a partial rescue of 
the H3.3 K27M-induced global hypomethylator phenotype 
CHOP (95). Furthermore, they showed that panobinostat was 
synergistic with GSKJ4 in decreasing cell viability of the H3.3 
K27M mutant DIPG cells (95). This presents an exciting option 
to target histone methylation and acetylation in clinical trials with 
the hope of combating HGGs.
As well as targeting HDAC inhibition, EZH2 inhibition 
provides an alternative mechanism to prevent aberrant histone 
methylation of target genes, which may promote cell differ-
entiation and prevent cell proliferation in several tissues (96). 
This has been demonstrated by preclinical studies in pediatric 
rhabdomyosarcoma (97). By using pharmacological inhibition 
of EZH2, the aggressiveness of rhabdomyosarcoma is less with a 
more differentiated phenotype (97). This provides further treat-
ment options for rhabdomyosarcoma by using EZH2 inhibitors 
as adjuvant therapy, thus with a likely possibility of increasing 
the effectiveness of current conventional treatment (97). EZH2 
overexpression is reported in many malignancies including lym-
phoma, breast cancer, and prostate cancer (98–100). Phase I pedi-
atric and phase II adult clinical trials are underway to investigate 
the efficacy of EZH2 inhibitors in hematological malignancies, as 
well as genetically defined solid tumors, including mesothelioma 
and malignant rhabdoid tumors (ClinicalTrials.gov identifier: 
NCT 02601937 and NCT 02601950).
Although this review has focused predominantly on aberra-
tions in histone H3K27 methylation, aberrations in methylation 
and acetylation of other histone proteins may provide positive or 
negative prognostic indicators for patients with glioma. Liu et al. 
reported the relationship between multiple histone modifications 
and patient prognosis (101). They analyzed by recursive parti-
tioning analysis, a retrospective cohort of patients with HGG, 
with progression-free survival and overall survival as the primary 
end points (101). Immunohistochemical analysis of H3K4, 
H4R3, H4K20, H3K9, H3K18, H4K12, and H4K16 from 230 
surgical HGG specimens suggested that lower levels of histone 
H3K4 methylation were associated with poor prognosis (101). In 
contrast to this, they found lower levels of histone acetylation in 
H3K18 were associated with a more favorable survival (101). This 
study highlights the potential prognostic impact of epigenetic 
changes in patients with HGG. This may provide future direction 
in selecting patients for optimal adjuvant treatment.
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Limitations of Therapeutic Targeting  
of epigenetics in HGG
The discovery of aberrant histone modifications propagating 
gliomagenesis has allowed the exploration of HDAC inhibitors 
and histone demethylase inhibitors in an attempt to combat an 
aggressive brain tumor. Current limitations of epigenetic target-
ing remain a challenge; in particular, the mechanism of HDAC 
inhibitors and their effect on cellular signaling pathways remains 
to be elucidated, and the effects of broadly altering functional 
epigenetic changes is unpredictable. Furthermore, there is 
intratumoral genetic heterogeneity, which may protect HGGs 
from being fully eradicated, as well as altering the uptake and 
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methods are yet to be found, which allow better penetration of 
HDAC inhibitors through the blood–brain barrier. For example, 
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which may give some rationale as to why they have so far failed to 
translate into effective therapies in clinical trials (104). The above 
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Targeting multiple epigenetic and genetic aberrations will 
likely be the key to succeeding in treating HGGs, and future 
clinical trials are needed to further explore combination thera-
pies, alongside novel techniques to improve the penetration of 
the blood–brain barrier.
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